



Discovery of ectoparasiticial hydrazoneotrifluoromethanesulfonanilides

Abdelselam Ali^a, Petr Fisara^b, Jamie A. Freemont^a, Stella Kyi^a, Adam G. Meyer^a, Andrew G. Riches^{a,*}, Roger M. Sargent^b, David G. Sawutz^c, Kathleen A. Turner^a, Kevin N. Winzenberg^a, Qi Yang^a

^aCSIRO Molecular and Health Technologies, Bag 10, Clayton South, Vic 3169, Australia

^bIntervet Schering-Plough Animal Health, 26 Artisan Rd, Seven Hills, NSW 2147, Australia

^cSchering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1300, USA

ARTICLE INFO

Article history:

Received 9 October 2009

Revised 12 November 2009

Accepted 16 November 2009

Available online 2 December 2009

Keywords:

Trifluoromethanesulfonanilide

Ectoparasiticide

Ctenocephalides felis (cat flea)

Rhipicephalus sanguineus (brown dog tick)

ABSTRACT

A series of hydrazoneotrifluorosulfonanilide derivatives were synthesized and evaluated for in vitro activity against the ectoparasites *Ctenocephalides felis* and *Rhipicephalus sanguineus*. Some compounds with excellent activity against tick were identified.

© 2009 Elsevier Ltd. All rights reserved.

Trifluoromethanesulfonanilide (TFMS) derivatives display insecticidal and acaricidal properties¹ which are exerted through uncoupling of oxidative phosphorylation in mitochondria.² As part of a program to discover new drugs to control commercially significant ectoparasites on companion animals,³ we recently reported the discovery of alkoxy and aryloxy iminoalkyl (oxime ether) TFMS derivatives (e.g., **1–3**, Fig. 1) with significant in vitro insecticidal and acaricidal activity.⁴ As an extension to that study, compound **4** was prepared as a prototype hydrazone analog of the oxime ethers and gave 100% mortality in a single-dose (1.26 µg/cm²) rapid screen for cat flea (*Ctenocephalides felis*) activity and 98% mortality in a rapid screen (10 µg/tick) against brown dog tick (*Rhipicephalus sanguineus*).⁵ By virtue of their additional site of substitution, hydrazones enable exploration of considerably greater chemical space than the corresponding oxime ethers. The 4-chloro-TFMS pharmacophore present in the most active oxime ether TFMS derivatives was maintained in the current study. The substituents on the hydrazone moiety were systematically varied in an effort to optimize parasiticial activity. Compounds were initially screened against cat flea, then selected active compounds were subjected to a rapid dog tick screen and, where appropriate, LC₅₀ (flea) and LD₅₀ (tick) determination.⁵

Hydrazone TFMS derivatives **4** and **7–45** were synthesized by condensation of ketones **5**^{6,7} with hydrazines **6**⁸ as indicated in Scheme 1 and Table 1.^{9,10} The hydrazones were obtained either as single isomers or mixtures of geometrical isomers.¹¹ Cyclic ana-

logs of **4** (compounds **46** and **47**) were prepared by condensation of phenylhydrazine with nitroaryl enone **48**,¹² using a modification of the method of Mannich and Lammering,¹³ followed by nitro reduction¹⁴ and amine triflation to give pyrazoline **46**. Dehydrogenation of **46** with DDQ gave pyrazole **47**.

Taking active compound **4** as the lead compound for an SAR study of hydrazone TFMS derivatives, we first varied R¹, while maintaining R² = Me and R³ = Ph. Phenyl and cyclohexyl groups (compounds **7** and **8**, respectively) both gave inferior flea activity to methyl.

By fixing R¹ as methyl or ethyl and R³ as phenyl, the effect of varying R² was next examined. While R² = H (compounds **9** and **10**) gave poor flea activity, various small alkyl groups (compounds **11–13**) gave good flea activity. Compounds **11** and **12** were also effective in the rapid tick assay, with the latter demonstrating an excellent LD₅₀. In contrast, allyl and propargyl substituents (compounds **14** and **15**, respectively) gave poor flea activity, while benzyl (compound **16**) gave good flea activity but poor tick activity.





Figure 1. Oxime ether trifluoromethanesulfonanilides and prototype hydrazone analog.

* Corresponding author. Tel.: +61 3 9545 2540; fax: +61 3 9545 2446.

E-mail address: andrew.riches@csiro.au (A.G. Riches).

Table 1Activity of hydrazonotrifluoromethanesulfonanilides **4**, **7–47** against *C. felis* (C.f.) and *R. sanguineus* (R.s.)


Compound	Method of preparation ^a	R ¹	R ²	R ³	C.f. % mortality 24 h	C.f. LC ₅₀ ^b (ng/cm ²)	R.s. % mortality 24 h ^b	R.s. LD ₅₀ ^b (μg/tick)
4	A	Me	Me	Ph	100		98	
7	A	Ph	Me	Ph	59			
8	A	Cyclohexyl	Me	Ph	14			
9	A	Me	H	Ph	20 ^c			
10	B	Et	H	2,4-DiCl-Ph	5 ^c			
11	C, A	Me	Et	Ph	100		100	
12	C, A	Me	<i>n</i> -Pr	Ph	100		75	1.2
13	A, D	Me	<i>i</i> -Pr	Ph	100			
14	C, A	Me	Allyl	Ph	59			
15	C, A	Me	Propargyl	Ph	38			
16	C, A	Me	Bn	Ph	100		33	
17	A	Me	Me	Me	66			
18	E, F	Me	Me	Cyclopentyl	85		98	1.01
19	E, F	Me	Me	Cyclohexyl	100		73	1.29
20	A, D	Me	Me	4-Cl-Ph	100	52.3	95	1.4
21	A, D	Me	Et	4-Cl-Ph	100		97	
22	A, D	Me	Et	4-F-Ph	100		100	
23	A, D	Me	Me	4-Br-Ph	100	42.7	100	
24	A, D	Me	Et	4-Br-Ph	100	27.3	95	5.6
25	A, D	Me	Me	4-CF ₃ -Ph	100		100	
26	A, D	Me	Me	4-Me-Ph	100	24.8	100	
27	A, D	Me	Me	3-Cl-Ph	100	14.6	100	2.6
28	A, D	Me	Me	3-F-Ph	100	13.4	100	2.0
29	A, D	Me	Et	3-F-Ph	100	7.46	98	2.1
30	G, H	Me	Me	3-CF ₃ -Ph	98		95	0.68
31	C, A	Me	Me	2-Cl-Ph	100		90	
32	A, D	Me	Et	2-Cl-Ph	89		83	
33	A, D	Me	Me	2-F-Ph	100	8.66	100	1.6
34	A, D	Me	Me	3,4-DiCl-Ph	99	35.3	78	3.0
35	A, D	Me	Me	3,5-DiCl-Ph	100	33.0	95	3.1
36	A, D	Me	Me	2,3-DiCl-Ph	100	30.8	70	4.0
37	A, D	Me	Et	2,4-DiCl-Ph	100		90	8.5
38	A, D	Me	<i>n</i> -Pr	2,6-DiCl-Ph	100		40	
39	A, D	Me	Me	2,5-DiCl-Ph	75			
40	I, A	Me	Me	2-Pyridyl	30			
41	A	Me		CH ₂ CH ₂ OCH ₂ CH ₂	100		95	0.75
42	A	Me		-(CH ₂) ₅ -	100		78	0.64
43	A	Me		-(CH ₂) ₆ -	23			
44	J	Me		-(CH ₂) ₄ -	100		93	0.74
45	A	Me		CH ₂ CH ₂ N(Me)CH ₂ CH ₂	48			
46	K		CH ₂ CH ₂	Ph	37			
47	L		CH=CH	Ph	43			
Fipronil						0.6–1.0		
Permethrin								0.13–0.35

^a See Scheme 1 for reaction conditions.^b No entry indicates that the compound was not assayed.^c Measured at 8 h.

With R¹ fixed as methyl and R² as methyl or ethyl, the effect of varying R³ was examined. Poor activity was observed when R³ = methyl (compound **17**), while cycloalkyl groups in this position (compounds **18** and **19**) showed good flea and excellent tick activity. Several 2, 3 or 4-monosubstituted aryl rings gave good flea and tick activity (compounds **20–33**) with **29** and **33** being representative of compounds which exhibited good potency across both dose response assays, and **30** giving the best tick activity. Various dichloro substituted aryl groups (compounds **34–39**) were generally effective in both rapid screens, but tick


potency (as measured by LD₅₀) was decreased relative to the monohaloaryl compounds. Replacement of the phenyl ring with the 2-pyridyl group (compound **40**) gave poor activity in the rapid flea screen.

Compounds **41**, **42** and **44**, in which R² and R³ formed morpholine, piperidine and pyrrolidine rings, respectively, were effective in the rapid flea screen and (together with **30**) showed the best tick activity of all the alkyldiazones in Table 1. In contrast to compound **4**, conformationally-restricted, cyclic analogs **46** and **47** gave poor activity in the rapid flea assay.



Scheme 1. Reagents and conditions:¹⁵ (A) EtOH, rt; (B) arylhydrazine-HCl, KOAc, EtOH, rt; (C) NaOH (aq), *n*-Bu₄NCl, R¹I, rt;¹⁶ (D) (i) NaH, DMF; (ii) R²I, rt, 16 h; (E) (i) cycloalkyl ketone, MeOH, rt; (ii) Na(CN)BH₃ HOAc, H₂O;¹⁷ (iii) R²I, K₂CO₃, CH₃CN, microwave, 120 °C; (iv) 6 N HCl, rt; (F) 6-HCl, NaHCO₃, toluene, reflux (Dean–Stark); (G) (i) arylhydrazine-HCl, PhCHO, K₂CO₃, EtOH; (ii) NaH, DMF, R²X; (iii) 12% HCl, reflux (Dean–Stark); (iv) NaOMe, MeOH; (H) toluene, reflux (Dean–Stark); (I) 2-chloropyridine, K₂CO₃, *i*-PrOH, microwave, 180 °C, 18 h; (J) 6-HCl, K₂CO₃, EtOH, rt; (K) (i) phenylhydrazine, EtOH, rt; (ii) SnCl₂, EtOH or H₂, Pd–C, HOAc, HCl (aq); (iii) Tf₂O, C₅H₅N; (L) DDQ, CH₂Cl₂.

In an effort to further optimize the insecticidal and/or acaricidal activity of hydrazone TFMS derivatives, the scope of the study was extended by condensing ketone TFMS **5** with a selection of acylhydrazines, semicarbazides, carbazates and *N*-amino heterocycles **49** to give compounds **50–72** (Scheme 2 and Table 2).




Scheme 2. Reagents and conditions:¹⁵ (M) EtOH, 100 °C, sealed tube, 16 h; (N) EtOH, rt, 16 h; (O) EtOH, 45 °C, 16 h; (P) (i) HCO₂H/H₂O (1:1), rt; (ii) Ac₂O, 100 °C;¹⁸ (iii) HCl, rt, 5 h;¹⁹ (Q) toluene, reflux (Dean–Stark); (R) (i) DMF, R²X, rt to 60 °C; (ii) EtOH/H₂O (3:2), reflux 6 h; (iii) EtOH, rt, 16 h; (S) (i) (R² = H) acrylonitrile; (ii) acid chloride, THF, NEt₃, –70 °C to rt; (T) 1-aminohydantoin-HCl, K₂CO₃, EtOH, 80 °C, 10 h.

Substituted phenacylhydrazones **51–54** showed good activity against flea and excellent activity against ticks. Replacement of the R² alkyl group with hydrogen was not as detrimental to the flea activity of the phenacylhydrazones **55** and **56** as it was to the alkylhydrazones in Table 1. When R² was a phenyl group (compound **57**) poor flea activity was obtained, while R² = cyanoethyl gave good tick control over a range of substituents X (compounds **58–62**). Semicarbazones **63** and **64** (R² = H) showed poor activity in the rapid flea assay. Alkoxy carbonyl hydrazones **65–69** retained high flea activity whilst delivering outstanding tick activity, with compounds **65** (LD₅₀ = 0.39 µg/tick) and **66** (LD₅₀ = 0.28 µg/tick) showing in vitro efficacy comparable to that of Permethrin. Oxazolidinones **70** and **71** and hydantoin **72** were active against both parasites.

The excellent cat flea and dog tick dose response results shown by several compounds in this study provide encouragement that a single compound may be developed to possess potent insecticidal and acaricidal activity. In particular, the potent acaricides **65** and **66** are candidates for subsequent in vivo evaluation as ectoparasite

Table 2

Activity of acyl hydrazoneotrifluoromethanesulfonanilides **50–72** against *C. felis* (C.f.) and *R. sanguineus* (R.s.).



Compound	Method of preparation ^a	R ¹	R ²	X	C.f. % mortality 24 h	C.f. LC ₅₀ ^b (ng/cm ²)	R.s. % mortality 24h ^b	R.s. LD ₅₀ ^b (µg/tick)
50	M	Me	Me	Ph	66			
51	N	Me	Me	4-Cl-Ph	100	51.3	100	1.8
52	O	Et	Me	4-Cl-Ph	100	39.3	100	1.49
53	N	Me	Me	2,4-DiCl-Ph	100	71.8	100	1.6
54	O	Et	Me	2,4-DiCl-Ph	88	42.3	100	2.0
55	N	Et	H	4-Cl-Ph	100	54.8	75	7.1
56	O	Et	H	2-Cl-Ph	86			
57	P, Q	Me	Ph	Me	22			
58	S, N	Me	CH ₂ CH ₂ CN	Me	100		90	0.53
59	S, N	Me	CH ₂ CH ₂ CN	Et	73			
60	S, N	Me	CH ₂ CH ₂ CN	<i>i</i> -Pr	100		100	
61	S, N	Me	CH ₂ CH ₂ CN	<i>n</i> -Pentyl	100		100	0.71
62	S, N	Me	CH ₂ CH ₂ CN	Ph	89		88	0.56
63	N	Me	H	NHPh	17			
64	N	Me	H	NH(4-CF ₃ -Ph)	18			
65	R	Me	Et	OMe	100		100	0.39
66	R	Et	Et	OMe	100		100	0.28
67	R	Me	Et	OEt	100		95	0.64
68	N	Me	Me	OEt	97		100	0.69
69	R, N	Et	Et	OEt	100		100	0.54
70	N	Me		–CH ₂ CH ₂ O–	100		95	0.99
71	Q	Et		–CH ₂ CH ₂ O–	100		100	
72	T	Me		–CH ₂ CONH–	100	43.8	100	1.7
Fipronil						0.6–1.0		
Permethrin								0.13–0.35

^a See Scheme 2 for reaction conditions.

^b No entry indicates that the compound was not assayed.

ticides. In view of the mechanism of action of the compounds reported herein, it is difficult to discern clear trends in the SAR data. It is likely that subtle structural differences which affect the physicochemical and pharmacokinetic properties of the hydrazone TFMS derivatives give rise to the observed differences in activity.²⁰

References and notes

- Mori, T.; Takada, Y.; Hatakoshi, M.; Matsuo, N. *Biosci. Biotechnol. Biochem.* **2004**, *68*, 425.
- McCracken, R. O.; Carr, A. W.; Stillwell, W. H.; Lipkowitz, K. B.; Boisvenue, R.; O'Doherty, G. O. P.; Wickiser, D. I. *Biochem. Pharmacol.* **1993**, *45*, 1873.
- Ali, A.; Bliese, M.; Rasmussen, J.-A. M.; Sargent, R. M.; Saubern, S.; Sawutz, D. G.; Wilkie, J. S.; Winkler, D. A.; Winzenberg, K. N.; Woodgate, R. C. J. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 993.
- Ali, A.; Altamore, T. M.; Bliese, M.; Fisara, P.; Liepa, A. J.; Meyer, A. G.; Nguyen, O.; Sargent, R. M.; Sawutz, D. G.; Winkler, D. A.; Winzenberg, K. N.; Ziebell, A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 252.
- C. felis* and *R. sanguineus* assays were conducted by the Centre for Entomological Research and Insecticide Technology, UNSW, Randwick, NSW, Australia or by Agrisearch Services Pty. Ltd, 50 Leewood Drive, Orange, NSW, Australia. Representative in vitro *C. felis* and *R. sanguineus* single dose assays and LC₅₀/LD₅₀ measurement protocols are described in Refs. 4 and 7.
- Trepka, R. D.; Harrington, J. K.; McConville, J. W.; McGurran, K. T.; Mendel, A.; Pauly, D. R.; Robertson, J. E.; Waddington, J. T. *J. Agric. Food. Chem.* **1974**, *22*, 1111.
- Meyer, A. G.; Winzenberg, K. N.; Sawutz, D. G.; Liepa, A. J. PCT Int. Appl. WO06/034333, 2006; *Chem. Abstr.* **2006**, *144*, 331134.
- Hydrazine starting materials were commercially available or were prepared according to Scheme 1/Table 1.
- Winzenberg, K. N.; Meyer, A. G.; Yang, Q.; Riches, A. G. U.S. Pat. Appl. Publ. US 2007/238,700; *Chem. Abstr.* **2007**, *147*, 421326.
- All synthetic intermediates and final products were characterized by ¹H NMR and MS.
- Upon attempted separation of isomers, individual isomers were observed to re-equilibrate to isomeric mixtures.
- Shen, W.; Coburn, C. A.; Bornmann, W. G.; Danishefsky, S. J. *J. Org. Chem.* **1993**, *58*, 611.
- Mannich, C.; Lammering, D. *Chem. Ber.* **1922**, *55*, 3510.
- Camacho, E.; León, J.; Entrena, A.; Velasco, G.; Carrión, M. D.; Escames, G.; Vivó, A.; Acuña-Castroviejo, D.; Gallo, M. A.; Espinosa, A. *J. Med. Chem.* **2004**, *47*, 5641.
- For detailed experimental procedures see Ref. 9.
- Baum, M. M.; Smith, E. H. *J. Chem. Soc., Perkin Trans. 1* **1993**, 2513.
- Ranatunge, R. R.; Augustyniak, M.; Bandarage, U. K.; Earl, R. A.; Ellis, J. L.; Garvey, D. S.; Janero, D. R.; Letts, L. G.; Martino, A. M.; Murty, M. G.; Richardson, S. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W.; Trocha, A. M.; Young, D. V. *J. Med. Chem.* **2004**, *47*, 2180.
- De Vries, H. J. *Chem. Ber.* **1894**, *27*, 15220.
- Behrend, R.; Reinsberg, W. *Justus Liebigs Ann. Chem.* **1910**, 377, 189.
- In response to a referee's concern that that hydrolysis of hydrazone derivatives may generate toxic metabolites, several hydrazones were tested on dogs for up to 28 days with no adverse effect.